| http://www.w3.org/ns/prov#value | - Recently a chemotherapy regimen including 5-FU/leucovorin, irinotecan and oxaliplatin was shown to increase median survival time to 10.5 months but was associated with a 48% incidence of grade 3/4 neutropenia (Conroy et al, J Clin Oncol (Meeting Abstracts) 2010; 28: 4010).
|
